Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David D Waters

Showing results (31-40 of 157) with videos related to

Pageof 16
Sort By:
Progress in Cardiovascular Diseases|July 2, 2005
Chlamydia pneumoniae and atherosclerosis: from Koch postulates to clinical trialsCatherine Liu, David D Waters
The Canadian Journal of Cardiology|July 1, 2014
Looking for coronary disease in patients with atrial fibrillationPayal Kohli, David D Waters
The Canadian Journal of Cardiology|October 9, 2017
Taking Hockey to Heart: Potential Coronary Risks of Watching Exciting GamesDavid D Waters, Stanley Nattel
The Canadian Journal of Cardiology|August 21, 2017
The Evolution of Myocardial Infarction: When the Truths We Hold To Be Self-Evident No Longer Have EvidenceDavid D Waters, Sripal Bangalore
The Canadian Journal of Cardiology|June 26, 2020
Will Colchicine Soon Be Part of Primary and Secondary Cardiovascular Prevention?Michelle Samuel, David D Waters
Current Opinion in Cardiology|July 7, 2011
Tobacco smoke and cardiovascular risk: a call for continued efforts to reduce exposurePaul Frey, David D Waters
Progress in Cardiovascular Diseases|August 16, 2003
Implications of cigarette smoking for the management of patients with acute coronary syndromesLouise Metz, David D Waters
Nature Clinical Practice. Cardiovascular Medicine|January 25, 2007
The SPARCL study: extending the indications of statin therapy for stroke?Doreen DeFaria Yeh, David D Waters
Journal of Clinical Lipidology|May 22, 2018
Variations in time to benefit among clinical trials of cholesterol-lowering drugsPhilip J Barter, David D Waters
The American Journal of Cardiology|September 5, 2002
Reassessment of National Cholesterol Education Program Adult Treatment Panel-III guidelines: one year laterBenjamin J Ansell, David D Waters,
Pageof 16

Showing results (31-40 of 157) with videos related to

Sort By:
Pageof 16
Progress in Cardiovascular Diseases|July 2, 2005
Chlamydia pneumoniae and atherosclerosis: from Koch postulates to clinical trialsCatherine Liu, David D Waters
The Canadian Journal of Cardiology|July 1, 2014
Looking for coronary disease in patients with atrial fibrillationPayal Kohli, David D Waters
The Canadian Journal of Cardiology|October 9, 2017
Taking Hockey to Heart: Potential Coronary Risks of Watching Exciting GamesDavid D Waters, Stanley Nattel
The Canadian Journal of Cardiology|August 21, 2017
The Evolution of Myocardial Infarction: When the Truths We Hold To Be Self-Evident No Longer Have EvidenceDavid D Waters, Sripal Bangalore
The Canadian Journal of Cardiology|June 26, 2020
Will Colchicine Soon Be Part of Primary and Secondary Cardiovascular Prevention?Michelle Samuel, David D Waters
Current Opinion in Cardiology|July 7, 2011
Tobacco smoke and cardiovascular risk: a call for continued efforts to reduce exposurePaul Frey, David D Waters
Progress in Cardiovascular Diseases|August 16, 2003
Implications of cigarette smoking for the management of patients with acute coronary syndromesLouise Metz, David D Waters
Nature Clinical Practice. Cardiovascular Medicine|January 25, 2007
The SPARCL study: extending the indications of statin therapy for stroke?Doreen DeFaria Yeh, David D Waters
Journal of Clinical Lipidology|May 22, 2018
Variations in time to benefit among clinical trials of cholesterol-lowering drugsPhilip J Barter, David D Waters
The American Journal of Cardiology|September 5, 2002
Reassessment of National Cholesterol Education Program Adult Treatment Panel-III guidelines: one year laterBenjamin J Ansell, David D Waters,
Pageof 16